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Abstract
Objective—To estimate the odds of morbidity and mortality associated with cesarean compared 
to vaginal delivery for breech fetuses delivered from 23 to 24 6/7 weeks gestational age (GA).
Study Design—Retrospective cohort study of state-level maternal and infant hospital discharge 
data linked to vital statistics for breech deliveries occurring between 23 and 24 6/7 weeks 
gestation in California, Missouri and Pennsylvania from 2000–2009 (N=1854). Analyses were 
stratified by GA (23–23 6/7 vs. 24–24 6/7).
Results—Cesarean was performed for 46% (335) and 77% (856) of 23- and 24-week breech 
fetuses. In multivariable analyses, overall survival was greater for cesarean-born neonates 
(AOR=3.98 95% CI=2.24, 7.06; AOR=2.91, 95% CI=1.76, 4.81). When delivered for non-
emergent indications, cesarean-born survivors were more than twice as likely to experience ‘Major 
Morbidity’ (IVH, BPD, NEC, asphyxia composite) (AOR 2.83, 95% CI=1.37, 5.84; AOR=2.07, 
95% CI=1.11, 3.86 at 23 and 24 weeks). Among intubated neonates, despite a short-term survival 
advantage, there was no difference in survival to >6-month corrected age (AOR=1.77, 95% CI 
=0.83, 3.74; AOR=1.50, 95% CI=0.81, 2.76). There was no difference in survival for intubated 
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23-week neonates delivered by cesarean for non-emergent indications, nor cesarean-born neonates 
weighing <500g.
Conclusion—Cesarean increased overall survival and major morbidity for breech periviable 
neonates. However, among intubated neonates, despite a short-term survival advantage, there was 
no difference in 6-month survival. Also, cesarean did not increase survival for neonates weighing 
<500g. Patients and providers should explicitly discuss the trade-offs related to neonatal mortality 
and morbidity, maternal morbidity, and implications for future pregnancies.
Keywords
periviable birth; breech presentation; mode of delivery; birth outcomes
Introduction
With technological gains in neonatal intensive care capabilities, the threshold to provide 
antenatal interventions to improve survival has decreased to earlier gestational ages. Even in 
the face of rising periviable cesarean rates,1, 2 the optimal mode of delivery for breech 
periviable neonates remains controversial, and it remains unclear whether cesarean delivery 
in the periviable period actually improves neonatal outcomes.2 In light of the known 
increase in maternal morbidity and implications for future pregnancies associated with 
classical cesarean,3 it is critically important that we have ample evidence to guide mode of 
delivery decisions at periviable gestational ages (GA). If cesarean does not confer 
substantial benefits to neonates, it is difficult to justify the added morbidity to mothers.
Many studies consider neonatal mortality and morbidity but often do not report outcomes by 
mode of delivery,4, 5 and those studies that do examine mode of delivery often describe only 
mortality without morbidity-related outcomes.2, 6–15 Furthermore, no randomized control 
trials of adequate size have compared planned vaginal delivery with planned cesarean for 
periviable neonates. Therefore, the literature leaves obstetricians ill-equipped to provide 
evidence-based recommendations and counseling to patients for periviable mode of delivery 
decisions.
The purpose of this study is to fill this gap in current knowledge by describing neonatal 
morbidity and mortality by mode of delivery for breech periviable fetuses. To do so, we aim 
to estimate the odds of neonatal morbidity and mortality associated with cesarean compared 
to vaginal delivery of breech fetuses delivered between 23 and 24 6/7 weeks GA.
Materials and Methods
Study Design and Population
We conducted a retrospective cohort study, analyzing state-level maternal and infant 
hospital discharge data, linked to birth and death certificate data, for California, Missouri, 
and Pennsylvania from 2000–2009. The Institutional Review Board (IRB) of the 
departments of health in California, Missouri, and Pennsylvania, and the Children’s Hospital 
of Philadelphia approved this study. The data were input by the departments of health for 
each respective state; then cleaned and validated using sources including birth certificates 
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and maternal and infant hospital data, with strong concordance (e.g. mode of delivery is over 
99.5% concordant). The records were created by linking birth certificate data with maternal 
hospital discharge records and newborn hospital discharge data records, or death certificate 
data in the event of a fetal demise. Records were linked using previously described 
methods.16 With these techniques, more than 98% of birth and death certificates are 
matched to maternal and newborn hospital records.17 These data have been utilized 
extensively in our and others’ publications.18–21
Live singleton births and ‘in-hospital’ fetal deaths occurring between 23 and 24 6/7 weeks 
of reported gestational age were included in the analysis. Because periviable births that are 
not resuscitated at the time of the delivery may potentially be classified as a fetal death,22 it 
was important that fetal deaths not be excluded entirely from the analysis. We sought to 
distinguish these types of fetal deaths from fetal deaths that occurred out of the hospital or as 
intrauterine demises. Such deaths were designated as ‘outpatient’ or ‘intrauterine’ fetal 
deaths using criteria described by Phibbs et al. in previous work22 and excluded from the 
analysis. (See Appendix A) Fetal anomalies were also excluded.
Variable Selection and Data Analysis
The primary predictor of interest was cesarean section (ICD 669.7x and 74.x), which had to 
be documented in the maternal or the infant record. Ultimately, documentation from the 
maternal record is reflected in all but 28 of the 8157 cases (99.0%). Breech neonates were 
identified by the following ICD-9 codes: 652.2, 652.20, 652.21, 652.23, and 763.0. 
Mortality-related outcomes of interest included: ‘Overall survival’ (defined as 6-month 
corrected age among intubated and non-intubated neonates) and survival to >24 hours, >1 
week, and >6-month corrected age among neonates for whom intubation was performed or 
attempted (designated by ICD-9 codes 96.01, 96.02, 96.03, 96.04, 96.05 and CPT code 
31500). Morbidity outcomes included: respiratory distress syndrome (RDS), 
bronchopulmonary dysplasia (BPD), grade III/IV intraventricular hemorrhage (IVH), 
necrotizing enterocolitis (NEC), retinopathy of prematurity (ROP), and asphyxia. Also 
included were composite outcome measures of ‘Major Morbidity’ designated as BPD, grade 
III/IV IVH, NEC, or asphyxia and a ‘Composite’ for death or asphyxia. ICD-9 codes used 
for specific diagnoses are listed in Appendix B. Maternal sociodemographic characteristics 
were also considered, including age in three categories (<18, 18–35, >35); race or ethnicity, 
designated in four categories (White, Black, Hispanic and Other); parity in four categories 
(0, 1, 2, 3 or more), education in two categories (<high school education or ≥high school 
education), median ZIP code income (<$20,000, $20,000–$40,000, $40,000–60,000, >
$60,000) to approximate household income, and insurance payer (Fee For Service (FFS), 
Health Maintenance Organization (HMO), Federally Insured, Uninsured, and Other). In an 
effort to control for potential confounding factors, sociodemographic characteristics 
(insurance, race, and age) associated with mode of delivery were included as covariates in 
the final models. Likewise, maternal comorbidities, pregnancy complications, and delivery 
indications were also included in the full model, specifically: preexisting diabetes (DM), 
gestational diabetes (GDM), chronic hypertension (cHTN), pregnancy induced hypertension 
(PIH), preterm labor, preterm premature rupture of membranes (PPROM), placental 
abruption, repeat cesarean, placenta previa, and chorioamnionitis. ICD-9 codes used for 
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specific diagnoses are listed in Appendix B. Finally, year of delivery was included because 
the incidence of cesarean increased over time in our cohort.
We conducted all analyses using SAS 9.2. Descriptive statistics were calculated using chi-
squared tests and Fisher’s exact test as appropriate. Logistic regression was performed for 
multivariable analyses, which included potential modifying factors such as 
sociodemographic factors, maternal comorbidities, pregnancy complications, and delivery 
indications in the model. Delivery hospital was also included as a fixed effect to account for 
potential clustering of outcomes at the level of the delivery hospital. We initially examined 
the relationship between mode of delivery and mortality and morbidity in the overall cohort. 
Separate analyses were conducted which excluded ‘emergent indications,’ designated as 
fetal distress, PIH, previa, and abruption. We reasoned that these indications typically 
require immediate delivery and may also be associated with poorer outcomes regardless of 
mode of delivery. We also examined survival over 3 time periods among the subset of 
neonates that were intubated. Finally, we constructed separate models to evaluate the 
potential interaction between cesarean delivery and birthweight in relationship to morbidity 
and mortality. Statistical tests were considered significant at α=.05, adjusted for multiple 
comparisons using the Bonferroni correction.
Results
Study Population
Our study population was comprised of 8157 maternal/infant observations. Among these, we 
identified 1854 (22.9%) breech deliveries that comprised our final study cohort. Table 1 
provides overall baseline sociodemographic and clinical characteristics for the mother and 
infant pairs, stratified by GA and mode of delivery. 77.9% of mothers were age 18–35. 
21.6% of the women were Black, 32.8% Hispanic, and 34.4% White. Approximately 27.6% 
of women had less than a high school education, and 50.0% were federally insured. Overall, 
45.5% and 76.6% of women delivering 23- and 24- week breech neonates were delivered by 
cesarean.
Women who were delivered by cesarean differed significantly from women who were not 
delivered by cesarean across parity, insurer, and educational categories (p<.01 for each). 
Mode of delivery also differed based on maternal comorbidities. Compared to women who 
delivered vaginally, women delivered by cesarean were more likely to have PIH (7.89% vs. 
1.66%, p=<.01) and a prior cesarean delivery (16.04% vs. 8.90%; p<.01); and less likely to 
have birth weight of <=500g (10.41% vs. 22.51%; p <.01).
Absolute Incidence and Adjusted Odds of Overall Survival by Mode of Delivery
Table 2 presents the absolute incidence and adjusted odds of ‘overall survival’ (includes all 
intubated and non-intubated neonates) for 23- and 24-week breech neonates in our study 
population, stratified by mode of delivery. Among the entire cohort of neonates delivered by 
cesarean at 23 weeks, the incidence of overall survival for cesarean-born neonates was 
52.2% (175/335) compared to 22.9% (94/402) for vaginally-born neonates. Survival among 
this group was statistically significantly higher (AOR 3.98, 95% CI=2.24, 7.06) for those 
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delivered by cesarean as compared to those who had a vaginal delivery in multivariable 
analyses. At 24 weeks, the overall survival among neonates delivered by cesarean was 
65.0% (556/856), compared to a survival of 41.0% (107/261) for vaginally delivered 
neonates. In multivariable analysis, at 24 weeks, breech neonates delivered by cesarean, 
when compared to vaginal delivery, experienced greater survival in the overall cohort (AOR 
2.91, 95% CI=1.76, 4.81). These associations remained statistically significant even after 
excluding emergent indications.
Morbidity among Survivors by Mode of Delivery and Gestational Age (GA)
Table 3 presents neonatal morbidity among intubated and non-intubated survivors, 
comparing cesarean and vaginal delivery by delivery indication and GA. Among intubated 
and non-intubated 23-week cesarean-born neonates who survived beyond 6-month corrected 
age, no differences were found in morbidity outcomes by mode of delivery. However, 
among those delivered for non-emergent indications, cesarean-born neonates were 
significantly more likely to experience each of the following: sepsis (AOR 3.62, 95% 
CI=1.78, 7.40), NEC (AOR 7.90, 95% CI=1.03, 60.57), and RDS (AOR 6.84, 95% CI=3.20, 
14.63). Moreover, ‘Major Morbidity’, defined as BPD, IVH, NEC or asphyxia, was nearly 3 
times as high for neonates delivered via cesarean for non-emergent indications compared to 
those delivered vaginally (AOR 2.83, 95% CI=1.37, 5.84).
Similar findings were noted among 24-week breech presenting neonates. Among intubated 
and non-intubated neonates delivered for all indications, no significant differences in 
morbidity were identified. However, 24-week cesarean-born neonates delivered for non-
emergent indications were more likely to experience BPD (AOR 2.09, 95% CI=1.05, 4.16), 
sepsis (AOR 2.06, 95% CI=1.11, 3.84), RDS (AOR 4.11, 95% CI=2.03, 8.32), and ROP 
(AOR 4.49, 95% CI=1.86, 10.82). Likewise, ‘Major Morbidity’ was twice as high among 
24-week breech neonates delivered by non-emergent cesarean (AOR 2.07, 95% CI=1.11, 
3.86) compared to those delivered vaginally.
Survival over Time among Intubated Neonates by Mode of Delivery
Table 4 presents the adjusted odds of surviving for >24 hours, >1 week, and >6 months 
corrected age by mode of delivery and indication for 23- and 24-week neonates who were 
intubated. Among intubated neonates, we found that cesarean-born 23-week neonates were 
significantly more likely to survive for 1 week (AOR 2.22, 95% CI=1.01, 4.87), but there 
was no difference in the likelihood of surviving 24 hours (AOR 1.44, 95% CI=0.46, 4.47) or 
to 6-month corrected age (AOR 1.77, 95% CI=0.83, 3.74) based on mode of delivery. 
Furthermore, when we limited the analysis to non-emergent indications for cesarean, there 
was no difference in survival at any time interval based on mode of delivery.
Findings differed for 24-week neonates. At 24 weeks, intubated breech neonates delivered 
by cesarean, when compared to vaginal delivery, experienced greater survival at the 24 hour 
and 1 week intervals; however, no difference was observed in likelihood of survival to 6-
month corrected age (AOR=1.81, 95% CI=0.72, 4.54). These associations remained even 
after excluding emergent indications.
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Additional Analyses
In the analysis that adjusted for the effect of clustering at the level of the delivery hospital, 
our results remained largely unchanged. Table 5 reveals the results of an analysis performed 
to evaluate the potential interaction between cesarean delivery and birth weight in 
relationship to morbidity and mortality. This analysis showed no difference in mortality for 
cesarean-born neonates weighing <500g (AOR=0.46 95% CI=0.12, 1.79). Separate analyses 
were also performed to evaluate the cesarean rate over time. The prevalence of cesarean 
delivery increased over time. However, the association between mode of delivery and 
neonatal morbidity and mortality did not change over the time frame of this study.
Comment
We set out to estimate the odds of morbidity and mortality associated with cesarean 
compared to vaginal delivery for breech periviable fetuses. Our findings demonstrate a 
survival advantage with cesarean delivery among the entire cohort of intubated and non-
intubated 23- and 24-week breech neonates. However, the odds of major neonatal morbidity 
among survivors were increased with cesarean performed for non-emergent indications. 
Furthermore, among the subset of intubated neonates, while the odds of short-term survival 
increased for 23- and 24-week neonates delivered by cesarean, their survival was no 
different beyond 6-month corrected age. Moreover, those intubated 23-week neonates 
delivered by cesarean for non-emergent indications were no more likely to survive at any 
time interval than those delivered by vaginal delivery. Finally, cesarean did not confer a 
survival benefit to neonates weighing <500g.
Other studies have reported a survival benefit for periviable neonates delivered by cesarean. 
Reddy et al. recently studied neonatal outcomes by attempted mode of delivery in a cohort 
of 24–32 week neonates.15 Among 388 breech presenting 24–28 week deliveries, attempted 
vaginal delivery was associated with a higher rate of mortality (25.2% vs. 13.2%). 
Unfortunately, it was difficult to interpret the relevance of these findings for periviable 
neonates because 24-week deliveries were grouped with deliveries up to 28 weeks, and 23-
week deliveries were not included. Malloy et al. studied vital statistics from more than 
120000 22–31 week neonates and reported a survival advantage among 22–25 week 
neonates delivered by cesarean (61.5% compared to 37.8%). This survival advantage was 
primarily attributable to a greater survival in the first 24 hours of life.6 In our initial analysis 
of the entire cohort of intubated and non-intubated breech neonates, we too found a survival 
advantage for cesarean-born neonates. However, for intubated neonates, this survival 
advantage was short-lived. For example, while cesarean-born 23-week breech neonates were 
more likely to survive from 24 hours to 1 week, they were no more likely to survive to 6-
month corrected age. Moreover, this short-term survival advantage likely reflects 
confounding by indication for delivery, because when we excluded non-emergent 
indications for cesarean, there was no longer a statistically significant association between 
mode of delivery and survival at any time interval for 23-week breech neonates.
Bottoms et al. previously reported that an obstetrician’s willingness to perform periviable 
cesarean more than tripled the odds of survival while doubling neonatal morbidity.24 
Similarly, we found that morbidity was greater among cesarean-born 23- and 24-week 
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neonates compared to vaginally-born neonates, but only when cesarean was performed for 
non-emergent indications. We were concerned that our results may be biased if obstetricians 
were more likely to deliver ‘sick’ or distressed babies by cesarean, resulting in greater 
morbidity among cesarean survivors. However, after excluding distressed and emergent 
deliveries, we noted greater, rather than attenuated, morbidity among the cesarean cohort. 
This may suggest that physician and fetal factors matter less in emergent decision-making; 
whereas, in non-emergent circumstances, physician judgments about survivability and/or 
parental preferences for intubation have a greater influence on clinical decision-making and 
outcomes. We sought to attend to this possible source of bias by calculating survival in a 
cohort of intubated neonates, and, indeed, we found that this attenuated the initially 
observed relationship between cesarean and survival.
There are limitations to the conclusions we can draw from these findings. Due to the 
limitations of the data set, we are unable to determine if the patterns of cesarean observed 
reflect institutional practice, maternal preference, or physician guidance. When we 
controlled for hospital as a fixed effect, there were no major differences in the overall 
findings. This suggests that institutional practice may not be a driving factor. Another 
limitation of the study is that we identified our predictor and outcome variables by ICD-9 
codes, not primary chart abstraction. This limits our ability to distinguish planned cesarean 
from unplanned cesarean and creates the risk for misclassification. However, this method 
allows for a large, population-based cohort that is needed to study these relatively rare 
events. The large cohort also allowed for stratified analysis to specifically focus on the 
association of cesarean and outcomes for breech presenting 23- and 24-week pregnancies. 
Finally, other unmeasured confounders, such as the administration of antenatal 
corticosteroids, may play a significant role in decision-making and actually account for the 
associations that we observed.
In closing, our study provides a more nuanced understanding of factors that may explain 
previous reports that cesarean confers a survival advantage for periviable neonates. In 
particular, our findings suggest that, for intubated 23- and 24-week breech neonates 
delivered by cesarean, this survival advantage is shortlived. Furthermore, we find no 
survival advantage for 23-week neonates when cesarean is performed for non-emergent 
indications. Additionally, we find that this short-term survival advantage can come at the 
expense of significant morbidity. In particular, we observed increased morbidity among 
intubated and non-intubated neonates delivered by cesarean for non-emergent indications. 
These findings have important clinical implications, particularly for the care of 23-week 
breech presenting fetuses. What parents consider to be a meaningful absolute difference in 
survival may not be consistent with what physicians designate as ‘clinically significant’ 
difference; and this may vary from parent to parent. Likewise, with survival time – some 
parents may find added days to weeks of survival to be meaningful; while others find it 
painstaking. These ‘quality vs. quantity’ of life determinations are best made with and by 
parents. Furthermore, as providers, we contend with numerous uncertainties—both in 
regards to where any given child will fall in the potential spectrum of disability, and what 
impact a classical cesarean will have on future reproductive outcomes for the mother. With 
such uncertainties, and poor prognostic capabilities available, these clinical deliberations 
clearly call for shared decision-making to occur between patients and providers. Together, 
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patients and providers must consider and explicitly discuss the inherent trade-offs related to 
neonatal mortality and morbidity, maternal morbidity, and implications for future 
pregnancies.
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Appendix A
‘Outpatient’ or ‘intrauterine’ fetal deaths were designated by the following ICD9 CM codes 
using criteria described by Phibbs et. al. in previous work.22 Fetal deaths with these 
diagnoses were excluded from the analysis:
Papyraceous fetus (ICD9 CM 646.01)
Intrauterine death (ICD9 CM 656.40, -41, or -43)
Decreased fetal movement (ICD9 CM 655.71)
Cord entanglement with compression (ICD9 CM 663.20)
Cord entanglement without compression (ICD9 CM 663.31)
Ruptured uterus before delivery (ICD9 CM 665.01)
Insertion of laminaria (ICD9 CM 69.93)
Hysterotomy to terminate pregnancy (ICD9 CM 74.91)
Appendix B
The following ICD9 CM codes were used to designate maternal and fetal characteristics 
included as covariates in the models:
Preexisting Diabetes Mellitus (ICD9 CM 250.xx, 648.0x, 357.2, 362.0, 362.01, 362.02, 
366.41)
Gestational Diabetes (ICD9 CM 648.8x)
Chronic Hypertension (ICD9 CM 642.0x, 642.1x, 642.2x)
Pregnancy Induced Hypertension (ICD9 CM 642.4x, 642.5x, 642.7x)
Preterm Labor (ICD9 CM 644.0x, 644.2x)
Preterm Premature Rupture of Membranes (ICD9 CM 658.1x, 658.2x)
Placental Abruption (ICD9 CM 641.2x)
Repeat Cesarean (ICD9 CM 654.2x and Birth Certificate Indicator)
Placenta Previa (ICD9 CM 641.0x, 641.1x)
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Chorioamnionitis (ICD9 CM 646.6x, 658.4x, 659.2x, 659.3x)
Asphyxia (ICD9 CM 738.9, 768.1, 768.3, 768.4, 768.5, 768.6, 768.7, 768.70, 768.71, 
768.72, 768.73)
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Table 3
Neonatal Morbidity among Intubated and Non-intubated Survivors Comparing Mode of Delivery by Delivery 
Indication and GA
All Indications Excluding Emergent Indications
23 Weeks GA 24 Weeks GA 23 Weeks GA 24 Weeks GA
AOR (95% CI)*†,‡ AOR (95% CI) AOR (95% CI) AOR (95% CI)
Asphyxia 0.47 (0.01, 38.85) 4.51 (0.11, 181.57) 0.87 (0.08, 9.15) 1.01 (0.18, 5.76)
BPD 0.87 (0.33, 2.32) 0.80 (0.38, 1.66) 2.28 (0.98, 5.31) 2.09 (1.05, 4.16)‖
Bacterial Sepsis 1.01 (0.37, 2.74) 1.13 (0.53, 2.41) 3.62 (1.78, 7.40)‖ 2.06 (1.11, 3.84)‖
IVH Grades III/IV 0.75 (0.14, 3.89) 0.78 (0.26, 2.29) 2.67 (0.87, 8.23) 1.39 (0.51, 3.83)
NEC 4.04 (0.36, 45.30) 1.32 (0.36, 4.79) 7.90 (1.03, 60.57)‖ 1.67 (0.53, 5.30)
RDS 2.01 (0.56, 7.27) 0.66 (0.22, 1.94) 6.84 (3.20, 14.63)‖ 4.11 (2.03, 8.32)‖
ROP 1.17 (0.40, 3.42) 1.57 (0.71, 3.49) 2.25 (0.91, 5.52) 4.49 (1.86,10.82)‖
Major Morbidity§ 0.83 (0.32, 2.20) 0.78 (0.37, 1.65) 2.83 (1.37, 5.84)‖ 2.07 (1.11, 3.86)‖
Composite§ 0.47 (0.01, 38.85) 4.51 (0.11, 181.57) 0.25 (0.12, 0.50)‖ 0.27 (0.14, 0.50)‖
*Corrected for multiple comparisons using the Bonferroni method (α=0.001389).
†Adjusted for insurance, maternal race, maternal age, chronic hypertension, diabetes, gestational diabetes, chorioamnionitis, pregnancy induced 
hypertension, preterm labor, premature rupture of membranes, placenta previa, placental abruption, previous Cesarean, and year.
‡Cesarean vs. vaginal delivery
§
Major Morbidity includes BPD, IVH, NEC, or asphyxia; Composite includes death or asphyxia
‖Significant at α=0.001389
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